Neuroprotectants FK-506 and cyclosporin A ameliorate the course of pilocarpine-induced seizures

Epilepsy Research

Volumn 73, Issue 2, 2007, Pages 151-155

  Setkowicz, Zuzanna ^a   Ciarach, Małgorzata ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Neuroprotection; Pilocarpine model of epilepsy; Seizure

Indexed keywords

CYCLOSPORIN; PILOCARPINE; TACROLIMUS;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; EPILEPTIC STATE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; SINGLE DRUG DOSE; SURVIVAL TIME;

ANIMALS; BEHAVIOR, ANIMAL; CYCLOSPORINE; MALE; NEUROPROTECTIVE AGENTS; PILOCARPINE; RATS; RATS, WISTAR; SEIZURES; STATUS EPILEPTICUS; TACROLIMUS;

EID: 33847316570     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2006.09.001     Document Type: Article

References (18)

1. Auer R.N., and Siesjo B.K. Biological differences between ischemia, hypoglycemia, and epilepsy. Ann. Neurol. 24 (1988) 699-707
2. Bartynski W.S., Zeigler Z., Spearman M.P., Lin L., Shadduck R.K., and Lister J. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am. J. Neuroradiol. 22 (2001) 1901-1914
3. Castilho R.F., Hansson O., and Brundin P. FK506 and cyclosporin A enhance the survival of cultured and grafted rat embryonic dopamine neurons. Exp. Neurol. 164 (2000) 94-101
4. Choi B.J., and Whang K.T. Change of hyperexcitability of hippocampus by cyclosporin A and its modulatory action by fentanyl. J. Korean Med. Sci. 17 (2002) 96-102
5. Friberg H., Ferrand-Drake M., Bengtsson F., Halestrap A.P., and Wieloch T. Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J. Neurosci. 18 (1998) 5151-5159
6. Fujikawa D.G. Prolonged seizures and cellular injury: understanding the connection. Epilepsy Behav. Suppl. 3 (2005) S3-S11
7. Furuichi Y., Katsuta K., Maeda M., Ueyama N., Moriguchi A., Matsuoka N., Goto T., and Yanagihara T. Neuroprotective action of tacrolimus (FK506) in focal and global cerebral ischemia in rodents: dose dependency, therapeutic time window and long-term efficacy. Brain Res. 965 (2003) 137-145
8. Leroy C., Roch C., Koning E., Namer I.J., and Nehlig A. In the lithium-pilocarpine model of epilepsy, brain lesions are not linked to changes in blood-brain barrier permeability: an autoradiographic study in adult and developing rats. Exp. Neurol. 182 (2003) 361-372
9. Meldrum B.S. Implications for neuroprotective treatments. Prog. Brain Res. 135 (2002) 487-495
10. Moia L.J., Matsui H., de Barros G.A., Tomizawa K., Miyamoto K., Kuwata Y., Tokuda M., Itano T., and Hatase O. Immunosuppressants and calcineurin inhibitors, cyclosporin A and FK506, reversibly inhibit epileptogenesis in amygdaloid kindled rat. Brain Res. 648 (1994) 337-341
11. Ruiz F., Alvarez G., Ramos M., Hernandez M., Bogonez E., and Satrustegui J. Cyclosporin A targets involved in protection against glutamate excitotoxicity. Eur. J. Pharmacol. 404 (2000) 29-39
12. Sanchez R.M., Dai W., Levada R.E., Lippman J.J., and Jensen F.E. AMPA/kainate receptor-mediated downregulation of GABAergic synaptic transmission by calcineurin after seizures in the developing rat brain. J. Neurosci. 25 (2005) 3442-3451
13. Setkowicz Z., Ciarach M., Guzik R., and Janeczko K. Different effects of neuroprotectants FK-506 and cyclosporin A on susceptibility to pilocarpine-induced seizures in rats with brain injured at different developmental stages. Epilepsy Res. 61 (2004) 63-72
14. Sullivan P.G., Rabchevsky A.G., Hicks R.R., Gibson T.R., Fletcher-Turner A., and Scheff S.W. Dose-response curve and optimal dosing regimen of cyclosporin A after traumatic brain injury in rats. Neuroscience 101 (2000) 289-295
15. Suzuki K., Omura S., Ohashi Y., Kawai M., Iwata Y., Tani K., Sekine Y., Takei N., and Mori N. FK506 facilitates chemical kindling induced by pentylenetetrazole in rats. Epilepsy Res. 46 (2001) 279-282
16. Tanaka C., Kawai R., and Rowland M. Dose-dependent pharmacokinetics of cyclosporin A in rats: events in tissues. Drug Metab. Dispos. 28 (2000) 582-589
17. Uchino H., Minamikawa-Tachino R., Kristian T., Perkins G., Narazaki M., Siesjo B.K., and Shibasaki F. Differential neuroprotection by cyclosporin A and FK506 following ischemia corresponds with differing abilities to inhibit calcineurin and the mitochondrial permeability transition. Neurobiol. Dis. 10 (2002) 219-233
18. Zawadzka M., and Kaminska B. A novel mechanism of FK506-mediated neuroprotection: downregulation of cytokine expression in glial cells. Glia 49 (2005) 36-51